![Life-sciences-healthcare-medicine-doctor-consult-AdobeStock_204066372](https://www.nortonrosefulbright.com/-/media/images/nrf/hero/life-sciences-healthcare-medicine-doctor-consult-adobestock_204066372.jpg?w=265&revision=2c8471a9-a0c6-4b1c-8320-4d1f3713a015&revision=5250222615397387904&hash=256FF231E0B62A2ABB3C5CF799F81CAB)
Publication
TGA shelves biosimilar and generic transparency measures
In late 2020, following almost 18 months of public and industry consultations conducted by the Therapeutic Goods Administration (TGA).
Several Commercial Division decisions adjudicating Anti-SLAPP law claims demonstrate the complexities that can be involved. Indeed, a recent decision dismissing claims brought by Donald Trump against The New York Times provides significant insight into the law’s current application.
In this update, Thomas J. Hall and Judith A. Archer address the evolution of these judicial approaches and recent cases reflecting their application.
Read the full New York Law Journal article, "Commercial division update: New York’s Anti-SLAPP Law: a powerful weapon."
Publication
In late 2020, following almost 18 months of public and industry consultations conducted by the Therapeutic Goods Administration (TGA).
Publication
The NSW Environment Protection Authority (EPA) recently released for public comment its draft Climate Change Assessment Requirements (CCARs) and draft Guide for Large Emitters (Guide).
Publication
The introduction of a minimum stockholding obligation under the Fuel Security Act 2021 (Cth) has underscored the importance of traditional liquid fuels to safeguarding Australia’s energy security as it navigates the energy transition.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023